These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25670381)

  • 21. FDA Modernization Act: implications for oncology.
    Morris L
    Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zohydro approval by food and drug administration: controversial or frightening?
    Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
    Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review.
    Brown BL; Mitra-Majumdar M; Joyce K; Ross M; Pham C; Darrow JJ; Avorn J; Kesselheim AS
    J Health Polit Policy Law; 2022 Dec; 47(6):649-672. PubMed ID: 35867548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.
    Wang B; Kesselheim AS
    BMJ; 2015 Sep; 351():h4679. PubMed ID: 26400844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
    Qureshi ZP; Seoane-Vazquez E; Rodriguez-Monguio R; Stevenson KB; Szeinbach SL
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):772-7. PubMed ID: 21574210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
    Daizadeh I
    Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines.
    Poirier AF; Murphy WR
    Clin Pharmacol Ther; 2016 Dec; 100(6):603-605. PubMed ID: 27513678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug development in inflammatory bowel disease: the role of the FDA.
    Lahiff C; Kane S; Moss AC
    Inflamm Bowel Dis; 2011 Dec; 17(12):2585-93. PubMed ID: 21484967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.